IMU-381
IMU-381 is a next generation molecule with improved overall properties, supported by a series of chemical derivatives. IMU-381 is currently in preclinical testing.
imux.comCrawled Nov 7, 2026
IMU-381 is a next generation molecule with improved overall properties, supported by a series of chemical derivatives. IMU-381 is currently in preclinical testing.
IMU-856 is an orally available and systemically acting small molecule modulator.
Immunic’s clinical pipeline includes oral small molecule therapies for multiple sclerosis, celiac disease, and other autoimmune disorders.
Immunic’s Video Corner features webcasts, earnings calls, scientific presentations, and clinical program updates on YouTube.
Vidofludimus calcium (IMU-838) is a small molecule investigational drug in development as an oral next-generation treatment option.
Immunic, Inc. (Nasdaq: IMUX), today announced the appointment of distinguished biopharmaceutical executive Erik Lundgren as Chief Executive Officer
NEW YORK, October 29, 2026 – Immunic, Inc. (Nasdaq: IMUX), today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET.
NEW YORK, November 2, 2026 – Immunic, Inc., today announced participation in the following investor conferences in November
Immunic, Inc.(Nasdaq: IMUX), today announced the presentation of additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838)
NEW YORK, September 25, 2025 – Immunic, Inc., today announced the presentation of key data in an oral and four poster presentations, including one late-breaking poster, at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Immunic offers career opportunities in developing therapies for autoimmune diseases.
Immunic Therapeutics is a biotech company focused on oral therapies for chronic inflammatory and autoimmune diseases.
Immunic Therapeutics develops oral therapies for autoimmune diseases using science and innovation.
Contact Immunic in the USA or Germany. Find phone numbers, email, and support for clinical trial participants via WhatsApp, Viber, or Telegram.
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.
Immunic’s Privacy Policy explains how the company collects, uses, and protects personal data and outlines user rights.
The Legal Disclaimer page provides official company details, contact information, and legal notices for Immunic.